US20160287839A1 - Apparatus and Method for Infusing an Immunotherapy Agent to a Solid Tumor for Treatment - Google Patents
Apparatus and Method for Infusing an Immunotherapy Agent to a Solid Tumor for Treatment Download PDFInfo
- Publication number
- US20160287839A1 US20160287839A1 US15/064,158 US201615064158A US2016287839A1 US 20160287839 A1 US20160287839 A1 US 20160287839A1 US 201615064158 A US201615064158 A US 201615064158A US 2016287839 A1 US2016287839 A1 US 2016287839A1
- Authority
- US
- United States
- Prior art keywords
- catheter
- lumen
- coating
- immunotherapy
- agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/0021—Catheters; Hollow probes characterised by the form of the tubing
- A61M25/0023—Catheters; Hollow probes characterised by the form of the tubing by the form of the lumen, e.g. cross-section, variable diameter
- A61M25/0026—Multi-lumen catheters with stationary elements
- A61M25/0029—Multi-lumen catheters with stationary elements characterized by features relating to least one lumen located at the middle part of the catheter, e.g. slots, flaps, valves, cuffs, apertures, notches, grooves or rapid exchange ports
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
- A61L29/04—Macromolecular materials
- A61L29/041—Macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
- A61L29/04—Macromolecular materials
- A61L29/06—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
- A61L29/08—Materials for coatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
- A61L29/08—Materials for coatings
- A61L29/085—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
- A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
- A61L29/145—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
- A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
- A61L29/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/01—Introducing, guiding, advancing, emplacing or holding catheters
- A61M25/02—Holding devices, e.g. on the body
- A61M25/04—Holding devices, e.g. on the body in the body, e.g. expansible
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/01—Filters implantable into blood vessels
- A61F2/013—Distal protection devices, i.e. devices placed distally in combination with another endovascular procedure, e.g. angioplasty or stenting
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/426—Immunomodulating agents, i.e. cytokines, interleukins, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/606—Coatings
- A61L2300/608—Coatings having two or more layers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/10—Materials for lubricating medical devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2420/00—Materials or methods for coatings medical devices
- A61L2420/02—Methods for coating medical devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2420/00—Materials or methods for coatings medical devices
- A61L2420/08—Coatings comprising two or more layers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M2025/0004—Catheters; Hollow probes having two or more concentrically arranged tubes for forming a concentric catheter system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/0021—Catheters; Hollow probes characterised by the form of the tubing
- A61M2025/0042—Microcatheters, cannula or the like having outside diameters around 1 mm or less
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/0043—Catheters; Hollow probes characterised by structural features
- A61M25/0045—Catheters; Hollow probes characterised by structural features multi-layered, e.g. coated
- A61M2025/0046—Coatings for improving slidability
- A61M2025/0047—Coatings for improving slidability the inner layer having a higher lubricity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
- A61M2025/1043—Balloon catheters with special features or adapted for special applications
- A61M2025/105—Balloon catheters with special features or adapted for special applications having a balloon suitable for drug delivery, e.g. by using holes for delivery, drug coating or membranes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
- A61M2025/1043—Balloon catheters with special features or adapted for special applications
- A61M2025/1052—Balloon catheters with special features or adapted for special applications for temporarily occluding a vessel for isolating a sector
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/0007—Special media to be introduced, removed or treated introduced into the body
Definitions
- the present invention relates devices and methods for administering immunotherapy to a patient, particularly for the treatment of patients with solid tumors.
- Immunomodulators include IL-2, IL-7, IL-12, Interferons, G-CSF, Imiquimod, CCL3, CCL26, CXCL7, cytosine phosphate-guanosine, oligodeoxynucleotides, and glucans, and all operate to systemically increase the patient's immune response.
- Vaccines comprise an infusion of antigen directly or antigen-activated dendritic cells, which activate the patients white blood cells.
- Modified cells are blood-derived immune cells from the patient which are engineered and incubated to grow to a large number of modified cells that specifically target a region of tumor. This approach, referred to as adoptive cell transfer (ACT) has generated remarkable responses in the small clinical trials in which it has been investigated.
- Check-point inhibitors include anti-PD-1, which block the patient's natural suppression of T-cells, thereby effectively increasing the time and number of T-cells that can fight the cancer.
- Immunotherapy practice has had success in “liquid” tumors, such as leukemia, where the therapy is easily delivered to the site of the cancer via intravenous injection or infusion. Further, immunotherapy has promise for solid tumors. However, delivery of the therapy with sufficient penetration into the tumors to allow the therapy to interact with the cancer cells remains a challenge.
- the immunotherapy agents are delivered by oral dosage, venous delivery, or catheter-based delivery to an organ of interest with a traditional microcatheter.
- Microcatheters can be delivered to localize delivery of the agent to the vascular system adjacent the organ of interest. However, various issues prevent desirable agent uptake at the tumor.
- systems and methods are provided for delivery of immunotherapy agents to a solid tumor.
- solid tumors can exhibit regions of low pressure within their vessels where there is robust flow, and they can have regions of high pressure where the vessels have become leaky and there is poor to no endogenous arterial flow. For these reasons, it is important to have an infusion system that does not rely solely on endogenous arterial flow to control delivery.
- immunotherapy systems and procedures should achieve several goals. Highly targeted delivery to the organ of interest should be obtained without the chance of back-flow into non-target regions. There should be the ability to increase pressure during infusion to overcome regions of high pressure in the tumor. More therapy should be deposited in the tumor than in the healthy tissue.
- the immunotherapy dose should deliver a maximum amount of intact cells or antibodies (a maximum percentage of healthy immunotherapy dose), and a minimum amount of damaged, destroyed cells, or activated cells during infusion.
- the anti-reflux catheter may have one or more additional attributes that are advantageous in the delivery of cancer treatments.
- these attributes can include the following.
- the catheter has self-centering capability that provides homogeneous distribution of therapy in a downstream branching network of vessels.
- the catheter includes an anti-reflux capability that blocks the retrograde flow of therapy into proximal non-target vessels proximal to the catheter tip.
- the system allows forward flow at a reduced pressure when not infusing therapy to target regions of low vascular resistance (tumor) and high capacitance (tumor).
- the valve and filter or a fully deployed balloon allows the pressure to be increased during infusion, with the pressure being modulated by the physician.
- a coating can be provided to the hub and inner lumen of the catheter to inhibit T-cell activation.
- a coating or construct can be provided to the hub and inner lumen of the catheter that optimize the wall shear during delivery of the therapy. By optimizing the wall shear gradient, the T-cells are subject to reduced trauma and maintain integrity during delivery while preventing clumping of the cells.
- the treatment catheter is used in a method of delivering an immunotherapy agent.
- the treatment includes infusion of immunotherapy cells, anti-bodies, and/or other biologics into the target organ, including a selected location within the target organ, while maintaining a high integrity of the cells of the immunotherapy dose.
- a modified Seldinger technique is used to introduce the catheter into the patient. More particularly, the catheter is introduced into the femoral artery, and then advanced up the aorta to the celiac axis. The catheter is then advanced into the left gastric artery. From the left gastric artery, the distal end of the catheter is advanced to the target artery that feeds the target organ. The catheter is then deployed for organ targeting.
- the immunotherapy agent including immunotherapy T-cells
- the immunotherapy agent is infused under pressure through the catheter and to the tumor. Infusion is continued until the prescribed dose of immunotherapy is completely infused. This can occur at sub-stasis, at stasis, or beyond stasis.
- the immunotherapy can be infused without any reflux.
- the immunotherapy can be infused beyond stasis without concern that the immunotherapy will reflux back toward the vessels of non-target tissues and/or organs.
- the anti-reflux catheter is removed from the patient, and an arterial closure device is used to close the arterial access point for the procedure.
- FIGS. 1A-1C are schematic diagrams of one exemplary embodiment of an apparatus of the invention respectively in an undeployed state, a deployed partially open state with blood passing in the distal direction, and a deployed fully open state where the blood flow is static.
- FIGS. 2A-2B are schematic diagrams of an exemplary embodiment of a valve having a braid component that is covered by a filter component in respectively an undeployed state and a deployed state.
- FIGS. 3A-3C are schematic diagrams of another exemplary embodiment of an apparatus of the invention respectively in an undeployed state, a deployed partially open state with blood passing in the distal direction, and a deployed fully open state where the blood flow is static.
- FIG. 4 is a graph showing the performance of the apparatus of FIGS. 1A-1C compared to the performance of a prior art end-hole catheter in delivering immunotherapy agent under pressure to target tissue.
- FIG. 5 is a schematic cross-sectional view across an embodiment of the anti-reflux catheter including oleophobic and/or a hydrophobic surface geometry (shown not to scale).
- FIG. 6 is a schematic cross-sectional view across an embodiment of the anti-reflux catheter including a surface geometry that minimizes wall shear (shown not to scale).
- proximal and distal are defined in reference to the user's hand, with the term “proximal” being closer to the user's hand, and the term “distal” being further from the user's hand, unless alternate definitions are specifically provided.
- the infusion catheter device is an infusion microcatheter with valve and filter, or filter valve, (hereinafter “microvalve catheter”) or an infusion microcatheter with a distal balloon (hereinafter “balloon catheter”), with both such devices collectively referred to herein as “anti-reflux infusion catheters”.
- the balloon catheter is manually operable between expanded (open) and collapsed (closed) configurations
- the microvalve catheter is a dynamic device, automatically moving between open and closed configurations based on local fluid pressure conditions to which the proximal and distal surfaces of the valve and filter are subject.
- an embodiment of an anti-reflux catheter 202 includes a flexible microcatheter 204 having a proximal end (not shown) and a distal end 206 .
- a lumen 208 extends through the microcatheter and has a distal orifice 210 , preferably coaxial with the axis of the catheter.
- a filter valve 212 is attached to the distal end 206 of the microcatheter, such that the orifice 210 opens into the proximal end 214 of the filter valve 212 .
- the filter valve 212 comprises a braided polymeric filamentary structure 216 that is adapted to dynamically open and close based on the relatively proximal and distal pressure conditions of the fluid to which the filter valve is subject within a vessel 224 .
- At least a portion of the braided filamentary structure 216 includes a polymeric filter 218 thereon, preferably deposited by electrospinning or electrostatic deposition to bond with the braided filamentary structure ( FIGS. 1A and 2B ).
- the filter 218 has a pore size not exceeding 500 ⁇ m. With such pore size, the filter 218 construct is semi-porous and allows elevated pressure differentials (greater distal pressure) to dissipate.
- the microcatheter 204 is adapted for use with an outer delivery catheter 220 , with the inner microcatheter 204 extending through the outer delivery catheter 220 .
- Longitudinal displacement of the outer catheter relative to the inner catheter allows the filter valve 212 to move from a non-deployed configuration ( FIG. 1A ) to a deployed configuration ( FIG. 1B ).
- the filter valve 212 is adapted to dynamically move between open and closed configurations ( FIG. 1B to FIG. 1C and back) based upon fluid pressure forces 222 , 226 applied to the proximal and distal sides of the filter valve when the device 202 is deployed within a vessel 224 ( FIG. 1C ).
- microvalve catheter is disclosed in detail in previously incorporated U.S. Pat. Nos. 8,500,775 and 8,696,698 and pending U.S. Ser. No. 14/330,456.
- microvalve catheters structurally and functionally similar to that described are sold by Surefire Medical, Inc., Riverside, Colo., as part of the Surefire Infusion System.
- another microvalve catheter 302 includes a catheter 304 having a first lumen 306 for infusing the embolizing agent out of a distal orifice 308 , and a second inflation lumen (not shown).
- An elastic membrane 310 is provided about a distal portion 312 of the catheter 304 and has a lower surface in communication with the inflation lumen to define a fluid inflatable balloon 314 .
- FIG. 3A shows the balloon 314 in a collapsed configuration
- FIG. 3B shows the balloon 314 in a partially expanded configuration (i.e., expanded insufficiently to reach across the vessel walls 224 )
- FIG. 3C shows the balloon 314 in a fully expanded configuration (i.e., expanded fully to the vessel walls 224 ). It is preferred that the balloon 314 be proximally offset from the distal tip 316 of the catheter 304 and particularly the orifice 308 of the first lumen.
- the balloon catheter device 302 may additionally include multiple balloons, optionally of different sizes, and either radially or longitudinally offset. The balloon is preferably provided for use with an outer delivery catheter 330 , as discussed below.
- the anti-reflux infusion catheter is adapted to self-center within a vessel 224 . This can be accomplished with the expandable balloon 314 being centered about the balloon catheter, or the expandable valve 212 ( FIGS. 1B and 1C ) expanding radially symmetrically about the catheter.
- the self-centering of the anti-reflux infusion catheter is effected to promote homogeneous distribution of immunotherapy in a downstream branching network of vessels.
- a centrally-positioned anti-reflux infusion catheter creates turbulent flow in a vessel to mix the infused immunotherapy evenly across the cross-sectional area of a vessel.
- such catheter blocks retrograde flow of immunotherapy into proximal non-target vessels proximal to the catheter tip, or a balloon or a valve on the catheter.
- the valve and filter or a partially deployed balloon permit forward flow at a reduced pressure when not infusing the immunotherapy to target regions of low vascular resistance (tumor) and high capacitance (tumor).
- the valve and filter or a fully deployed balloon allows the infusion pressure to be increased during infusion, with the pressure being modulatable by the physician.
- the pressure being modulatable by the physician.
- an increase in delivery and penetration of the immunotherapy into regions of the tumor that are naturally subject to high pressure conditions is effected.
- FIG. 4 it is seen that a microvalve anti-reflux catheter of the type available from Surefire Medical, Inc. allows infusion to generate substantially elevated distal pressures relative to a prior art end-hole catheter (with no anti-reflux structure or function).
- the pressure applied by the Surefire device dissipated after infusion, as fluid was able to diffuse back through the semi-porous membrane of the valve and filter.
- the end-hole catheter was unable to generate pressure gradients distal to the tip during infusion as fluid was able to reflux, equalizing fluid pressure in the system.
- an inner lining of the lumen 208 of the catheter 204 is tailored to minimize surface energy and interaction with T-cells.
- the inner lining of the lumen 208 is coated with one or more polymers 230 ( FIG. 2A ) such as silicones and silicone oils, polypropylene, polyethylene and fluoropolymers such as polytetrafluoroethylene, polyvinylidene fluoride, fluorinated ethylene-propylene, and perfluorinated elastomers.
- an inner lining surface 232 a of the lumen 208 a of the catheter 204 a is structurally patterned to create an oleophobic and/or a hydrophobic surface geometry ( FIGS. 2A and 5 ).
- the inner lining surface 232 a can be patterned to include micro and/or nano scale ridges, pillars, or other features that generate a rough hydrophobic surface.
- Such features may be further chemically modified with fluoropolymers 230 a (such as perfluoropolyether), silicones, or other chemical entities to enhance the hydrophobic effect and/or to provide oleophobic functionality to the surface features.
- the inner lining surface of the lumen can be modified with hydrogels that can act to inhibit T-cell attachment and/or activation or can be used as protectants against fluid-mechanical cell damage.
- hydrogels that can act to inhibit T-cell attachment and/or activation or can be used as protectants against fluid-mechanical cell damage.
- Such polymers are typically hydrophilic and electrically neutral and hydrogen bond acceptors rather than hydrogen bond donors.
- Examples include but are not limited to polyvinyl alcohol (PVA) and chemically modified PEO-(X) hybrid gels, poly(ethylene) glycol (PEG) and chemically modified PEG-(X) hybrid gels (PEGylated polymers), polyethylene oxide (PEO) and chemically modified PEO-(X) hybrid gels, Poly(acrylic acid), 2-hydroxyethyl methacrylate (HEMA)-based polymers and zwitterionic hydrogels such as phosphobetaine, sulfobetaine, and carboxybetaine which can display variable surface activity based on environmental pH.
- natural or artificial protein layers can be provided to the lumen surface or the hydrogel network and can have specific cellular stabilizing activities. Such a protein layer can include cytokines.
- Such polymers and proteins can be attached in cross-linked networks or in “brushy” layers of polymer strands.
- Methodology includes self-assembled monolayers of short chain hydrogels or peptides attached to the inner surface of the lumen of the catheter using a variety of covalent or ionic bonding chemistry and layer-by-layer self-assembly of tailored functionality nano-composite gels.
- an alternative or additional coating or structure can be provided to the hub and/or inner lining of the lumen of the catheter that will reduce the wall shear stress during delivery of the immunotherapy.
- a coating or structure can include a hydrophilic coating, a hydrophobic coating, or a small ‘brushy’ fibrous layer that acts to create a region of low flow or no flow along the wall of the catheter.
- the coating can include glycocalyx or a glycocalyx-mimicking layer.
- Glycocalyx is a glycoprotein-polysaccharide, including several carbohydrate moieties of membrane glycolipids and glycoproteins.
- the glycocalyx is a small, irregularly shaped layer extending approximately 50-100 nm into the lumen of a blood vessel, but can be up to 11 ⁇ m thick.
- the coating in the lumen can mimic such biological structure.
- wall shear stress along the lumen can be modified by incorporating a surfactant coating 230 b into the lining of the lumen of the catheter.
- the wall shear stress can be modified by extruding the lumen 208 b of the catheter 204 b with features, including elongate channels 234 b formed along length and open to the central lumen 208 b ( FIG. 6 ).
- Such channels 234 b are either smaller or bigger than the diameter of a T-cell (e.g., less than 7 microns across or greater than 20 microns across) so as to prevent the channels from engaging and filling with captured T-cells.
- the channels will fill with fluid, but no T cells, and the peripheral channel-fluid will guide passage and minimize wall shear stress of the T cells through the lumen.
- the catheter is negatively charged. In one manner, this can be effected by providing wires or even a braid about the lumen and applying a negative voltage to the wires (with no/negligible current during use); in another manner, the catheter is constructed with a negatively charged polymer.
- the immunotherapy agent is naturally negatively charge (as T-cells have negative surface charge). Then, the T-cells in the immunotherapy agent are repelled from the lumen surface to thereby reduce the shear stress upon infusion of the immunotherapy agent.
- the wall shear stress can be minimized by incorporating a surfactant into the immunotherapy fluid containing the T cells.
- the surfactant can be premixed with the immunotherapy agent or mixed at the time of infusion.
- a modified Seldinger technique is utilized.
- the Seldinger technique which is well-known and will not be described in detail herein, access is provided from the thigh to the femoral artery and a guidewire is advanced to the aorta.
- the delivery catheter is advanced over the guidewire.
- an anti-reflux infusion catheter is advanced through the delivery catheter and over the guidewire.
- the anti-reflux catheter is displaced relative to the delivery catheter to expose the distal end of the anti-reflux catheter.
- the anti-reflux catheter is deployed.
- the immunotherapy agent including immunotherapy T-cells
- the immunotherapy agent is infused through the catheter and under pressure to the tumor. Infusion is continued until the prescribed dose of immunotherapy is completely infused. This can occur at sub-stasis, at stasis, or beyond stasis.
- the immunotherapy can be infused without any reflux.
- the immunotherapy can be infused beyond stasis without concern that the immunotherapy will reflux back toward the vessels of non-target tissues and/or organs.
- the anti-reflux catheter is removed from the patient, and an arterial closure device is used to close the arterial access point for the procedure.
Abstract
Description
- This application claims priority under 35 U.S.C. §119(e) to U.S. provisional application Ser. No. 62/140,651, filed Mar. 31, 2015, the entire contents of which are hereby incorporated herein by reference.
- 1. Field of the Invention
- The present invention relates devices and methods for administering immunotherapy to a patient, particularly for the treatment of patients with solid tumors.
- 2. State of the Art
- For many years the basic treatment for cancer has consisted of surgery, chemotherapy and radiation therapy. More recently, drugs that target cancer cells, such as imatinib (Gleevac®) and trastuzumab (Herceptin®) by guiding themselves to specific molecular changes seen in the cancer cells have also become standard treatments for a number of cancers.
- Now, therapies that take advantage of a patient's immune system to fight their cancers are in clinical use or in development and gaining interest. There are four basic versions of immunotherapy products today, which can be used alone or in combination. These immunotherapy products include immunomodulators, vaccines, modified cells and check-point inhibitors.
- Immunomodulators include IL-2, IL-7, IL-12, Interferons, G-CSF, Imiquimod, CCL3, CCL26, CXCL7, cytosine phosphate-guanosine, oligodeoxynucleotides, and glucans, and all operate to systemically increase the patient's immune response. Vaccines comprise an infusion of antigen directly or antigen-activated dendritic cells, which activate the patients white blood cells. Modified cells are blood-derived immune cells from the patient which are engineered and incubated to grow to a large number of modified cells that specifically target a region of tumor. This approach, referred to as adoptive cell transfer (ACT) has generated remarkable responses in the small clinical trials in which it has been investigated. Check-point inhibitors include anti-PD-1, which block the patient's natural suppression of T-cells, thereby effectively increasing the time and number of T-cells that can fight the cancer.
- Immunotherapy practice has had success in “liquid” tumors, such as leukemia, where the therapy is easily delivered to the site of the cancer via intravenous injection or infusion. Further, immunotherapy has promise for solid tumors. However, delivery of the therapy with sufficient penetration into the tumors to allow the therapy to interact with the cancer cells remains a challenge.
- In current practice, the immunotherapy agents are delivered by oral dosage, venous delivery, or catheter-based delivery to an organ of interest with a traditional microcatheter.
- In venous delivery, the agent is generally infused into the patient through a peripherally inserted central catheter (PICC) or a port implanted in the patient. PICCs and ports can remain in place for several weeks or months and are used to reduce the number of times that a patient is subject to needle sticks and to reduce risk of tissue and muscle damage that can occur with a standard IV. While a PICC or port may be suitable for infusion of a chemotherapy treatment agent, which is generally circulated throughout the patient's circulation system, or for a “liquid” tumor, it may not be suitable for delivery of the immunotherapy agent to a solid tumor.
- Microcatheters can be delivered to localize delivery of the agent to the vascular system adjacent the organ of interest. However, various issues prevent desirable agent uptake at the tumor.
- In accord with the invention, systems and methods are provided for delivery of immunotherapy agents to a solid tumor.
- Solid tumors undergo angiogenesis, which creates unique vascular characteristics compared to healthy tissue. Solid tumors often have regions of high vascular density, a reduced resistance to flow, and a high capacitance for therapy. As a result of the unregulated tumor angiogenic process, a dense branching network of vessels is formed in the tumor. The formed dense network has a different vessel structure than health vessels. A healthy vessel is encased in endothelium, which maintains vascular tone and provides resistance to flow. Tumor vessels have a deteriorated endothelium and lack tone; this results in lower resistance to flow. Also, the dense network of vessels creates a relatively large vascular volume for the relative volume of the tissue, permitting a significantly higher volume of therapy to be deposited in the tumor compared to healthy tissue. Further, solid tumors can exhibit regions of low pressure within their vessels where there is robust flow, and they can have regions of high pressure where the vessels have become leaky and there is poor to no endogenous arterial flow. For these reasons, it is important to have an infusion system that does not rely solely on endogenous arterial flow to control delivery.
- In view of these identified factors, it is believed by the inventors that immunotherapy systems and procedures should achieve several goals. Highly targeted delivery to the organ of interest should be obtained without the chance of back-flow into non-target regions. There should be the ability to increase pressure during infusion to overcome regions of high pressure in the tumor. More therapy should be deposited in the tumor than in the healthy tissue. The immunotherapy dose should deliver a maximum amount of intact cells or antibodies (a maximum percentage of healthy immunotherapy dose), and a minimum amount of damaged, destroyed cells, or activated cells during infusion. In addition, it is desirable to have a catheter deliver a homogenous immunotherapy dose across a vessel, including across a vessel branching network.
- In accord with these goals, an immunotherapy treatment is delivered through a fully or partially deployed intravascular pressure modulating anti-reflux catheter, such as a catheter with microvalve and filter or a balloon catheter.
- Further, the anti-reflux catheter may have one or more additional attributes that are advantageous in the delivery of cancer treatments. By way of example, these attributes can include the following. The catheter has self-centering capability that provides homogeneous distribution of therapy in a downstream branching network of vessels. The catheter includes an anti-reflux capability that blocks the retrograde flow of therapy into proximal non-target vessels proximal to the catheter tip. The system allows forward flow at a reduced pressure when not infusing therapy to target regions of low vascular resistance (tumor) and high capacitance (tumor). The valve and filter or a fully deployed balloon allows the pressure to be increased during infusion, with the pressure being modulated by the physician. An increased pressure allows increased delivery to and penetration into regions of the tumor that are naturally subject to high pressure conditions. According to another aspect of the device, a coating can be provided to the hub and inner lumen of the catheter to inhibit T-cell activation. According to yet another aspect of the device, a coating or construct can be provided to the hub and inner lumen of the catheter that optimize the wall shear during delivery of the therapy. By optimizing the wall shear gradient, the T-cells are subject to reduced trauma and maintain integrity during delivery while preventing clumping of the cells.
- In accord with the method described herein, the treatment catheter is used in a method of delivering an immunotherapy agent. The treatment includes infusion of immunotherapy cells, anti-bodies, and/or other biologics into the target organ, including a selected location within the target organ, while maintaining a high integrity of the cells of the immunotherapy dose.
- A modified Seldinger technique is used to introduce the catheter into the patient. More particularly, the catheter is introduced into the femoral artery, and then advanced up the aorta to the celiac axis. The catheter is then advanced into the left gastric artery. From the left gastric artery, the distal end of the catheter is advanced to the target artery that feeds the target organ. The catheter is then deployed for organ targeting.
- Then, the immunotherapy agent, including immunotherapy T-cells, is infused under pressure through the catheter and to the tumor. Infusion is continued until the prescribed dose of immunotherapy is completely infused. This can occur at sub-stasis, at stasis, or beyond stasis. At stasis, the immunotherapy can be infused without any reflux. Further, by either manually inflating the balloon of a balloon catheter to block flow past the balloon in the vessel, or by use of the dynamically adjustable anti-reflux infusion catheter with valve, the immunotherapy can be infused beyond stasis without concern that the immunotherapy will reflux back toward the vessels of non-target tissues and/or organs.
- After the infusion of the immunotherapy agent, the anti-reflux catheter is removed from the patient, and an arterial closure device is used to close the arterial access point for the procedure.
-
FIGS. 1A-1C are schematic diagrams of one exemplary embodiment of an apparatus of the invention respectively in an undeployed state, a deployed partially open state with blood passing in the distal direction, and a deployed fully open state where the blood flow is static. -
FIGS. 2A-2B are schematic diagrams of an exemplary embodiment of a valve having a braid component that is covered by a filter component in respectively an undeployed state and a deployed state. -
FIGS. 3A-3C are schematic diagrams of another exemplary embodiment of an apparatus of the invention respectively in an undeployed state, a deployed partially open state with blood passing in the distal direction, and a deployed fully open state where the blood flow is static. -
FIG. 4 is a graph showing the performance of the apparatus ofFIGS. 1A-1C compared to the performance of a prior art end-hole catheter in delivering immunotherapy agent under pressure to target tissue. -
FIG. 5 is a schematic cross-sectional view across an embodiment of the anti-reflux catheter including oleophobic and/or a hydrophobic surface geometry (shown not to scale). -
FIG. 6 is a schematic cross-sectional view across an embodiment of the anti-reflux catheter including a surface geometry that minimizes wall shear (shown not to scale). - With reference to the human body and components of the devices and systems described herein which are intended to be hand-operated by a user, the terms “proximal” and “distal” are defined in reference to the user's hand, with the term “proximal” being closer to the user's hand, and the term “distal” being further from the user's hand, unless alternate definitions are specifically provided.
- Methods are provided herein for infusing an immunotherapy agent to a tumor site for treatment of cancer. The method includes use of an infusion catheter device. In accord with the method, the infusion catheter device is an infusion microcatheter with valve and filter, or filter valve, (hereinafter “microvalve catheter”) or an infusion microcatheter with a distal balloon (hereinafter “balloon catheter”), with both such devices collectively referred to herein as “anti-reflux infusion catheters”. Whereas the balloon catheter is manually operable between expanded (open) and collapsed (closed) configurations, the microvalve catheter is a dynamic device, automatically moving between open and closed configurations based on local fluid pressure conditions to which the proximal and distal surfaces of the valve and filter are subject.
- By way of example, referring to
FIGS. 1A through 1C , an embodiment of ananti-reflux catheter 202 includes aflexible microcatheter 204 having a proximal end (not shown) and adistal end 206. Alumen 208 extends through the microcatheter and has adistal orifice 210, preferably coaxial with the axis of the catheter. Afilter valve 212 is attached to thedistal end 206 of the microcatheter, such that theorifice 210 opens into theproximal end 214 of thefilter valve 212. Thefilter valve 212 comprises a braided polymericfilamentary structure 216 that is adapted to dynamically open and close based on the relatively proximal and distal pressure conditions of the fluid to which the filter valve is subject within avessel 224. At least a portion of the braidedfilamentary structure 216 includes apolymeric filter 218 thereon, preferably deposited by electrospinning or electrostatic deposition to bond with the braided filamentary structure (FIGS. 1A and 2B ). Thefilter 218 has a pore size not exceeding 500 μm. With such pore size, thefilter 218 construct is semi-porous and allows elevated pressure differentials (greater distal pressure) to dissipate. Themicrocatheter 204 is adapted for use with anouter delivery catheter 220, with theinner microcatheter 204 extending through theouter delivery catheter 220. Longitudinal displacement of the outer catheter relative to the inner catheter (in the direction of arrow 221) allows thefilter valve 212 to move from a non-deployed configuration (FIG. 1A ) to a deployed configuration (FIG. 1B ). Once deployed, thefilter valve 212 is adapted to dynamically move between open and closed configurations (FIG. 1B toFIG. 1C and back) based uponfluid pressure forces 222, 226 applied to the proximal and distal sides of the filter valve when thedevice 202 is deployed within a vessel 224 (FIG. 1C ). Such a microvalve catheter is disclosed in detail in previously incorporated U.S. Pat. Nos. 8,500,775 and 8,696,698 and pending U.S. Ser. No. 14/330,456. In addition, microvalve catheters structurally and functionally similar to that described are sold by Surefire Medical, Inc., Westminster, Colo., as part of the Surefire Infusion System. - Turning now to
FIGS. 3A through 3C , as another example, anothermicrovalve catheter 302 includes acatheter 304 having afirst lumen 306 for infusing the embolizing agent out of adistal orifice 308, and a second inflation lumen (not shown). Anelastic membrane 310 is provided about adistal portion 312 of thecatheter 304 and has a lower surface in communication with the inflation lumen to define a fluidinflatable balloon 314.FIG. 3A shows theballoon 314 in a collapsed configuration,FIG. 3B shows theballoon 314 in a partially expanded configuration (i.e., expanded insufficiently to reach across the vessel walls 224), andFIG. 3C shows theballoon 314 in a fully expanded configuration (i.e., expanded fully to the vessel walls 224). It is preferred that theballoon 314 be proximally offset from thedistal tip 316 of thecatheter 304 and particularly theorifice 308 of the first lumen. Theballoon catheter device 302 may additionally include multiple balloons, optionally of different sizes, and either radially or longitudinally offset. The balloon is preferably provided for use with anouter delivery catheter 330, as discussed below. - In accord with one preferred aspect of the anti-reflux infusion catheter used in the method, the anti-reflux infusion catheter is adapted to self-center within a
vessel 224. This can be accomplished with theexpandable balloon 314 being centered about the balloon catheter, or the expandable valve 212 (FIGS. 1B and 1C ) expanding radially symmetrically about the catheter. The self-centering of the anti-reflux infusion catheter is effected to promote homogeneous distribution of immunotherapy in a downstream branching network of vessels. That is, in distinction from a single streamline of delivery from a prior art end-hole catheter, a centrally-positioned anti-reflux infusion catheter creates turbulent flow in a vessel to mix the infused immunotherapy evenly across the cross-sectional area of a vessel. - In accord with another preferred aspect of the anti-reflux infusion catheter, such catheter blocks retrograde flow of immunotherapy into proximal non-target vessels proximal to the catheter tip, or a balloon or a valve on the catheter. In accord with yet another aspect of the anti-reflux infusion catheter, the valve and filter or a partially deployed balloon permit forward flow at a reduced pressure when not infusing the immunotherapy to target regions of low vascular resistance (tumor) and high capacitance (tumor).
- In accord with yet another aspect of the anti-reflux infusion catheter, the valve and filter or a fully deployed balloon allows the infusion pressure to be increased during infusion, with the pressure being modulatable by the physician. By increasing the pressure, an increase in delivery and penetration of the immunotherapy into regions of the tumor that are naturally subject to high pressure conditions is effected. Referring to
FIG. 4 , it is seen that a microvalve anti-reflux catheter of the type available from Surefire Medical, Inc. allows infusion to generate substantially elevated distal pressures relative to a prior art end-hole catheter (with no anti-reflux structure or function). The pressure applied by the Surefire device dissipated after infusion, as fluid was able to diffuse back through the semi-porous membrane of the valve and filter. The end-hole catheter was unable to generate pressure gradients distal to the tip during infusion as fluid was able to reflux, equalizing fluid pressure in the system. - In accord with another aspect of the anti-reflux catheter (with reference to
device 202, but equally applicable to device 302), an inner lining of thelumen 208 of thecatheter 204 is tailored to minimize surface energy and interaction with T-cells. The inner lining of thelumen 208 is coated with one or more polymers 230 (FIG. 2A ) such as silicones and silicone oils, polypropylene, polyethylene and fluoropolymers such as polytetrafluoroethylene, polyvinylidene fluoride, fluorinated ethylene-propylene, and perfluorinated elastomers. - In accord with another aspect of the anti-reflux catheter, as an addition to or alternative to the coating described above, an
inner lining surface 232 a of thelumen 208 a of the catheter 204 a is structurally patterned to create an oleophobic and/or a hydrophobic surface geometry (FIGS. 2A and 5 ). In accord with such aspect, theinner lining surface 232 a can be patterned to include micro and/or nano scale ridges, pillars, or other features that generate a rough hydrophobic surface. Such features may be further chemically modified with fluoropolymers 230 a (such as perfluoropolyether), silicones, or other chemical entities to enhance the hydrophobic effect and/or to provide oleophobic functionality to the surface features. - In accord with another aspect of the anti-reflux catheter, as an addition to or alternative to the coatings and structure described above, the inner lining surface of the lumen can be modified with hydrogels that can act to inhibit T-cell attachment and/or activation or can be used as protectants against fluid-mechanical cell damage. Such polymers are typically hydrophilic and electrically neutral and hydrogen bond acceptors rather than hydrogen bond donors. Examples include but are not limited to polyvinyl alcohol (PVA) and chemically modified PEO-(X) hybrid gels, poly(ethylene) glycol (PEG) and chemically modified PEG-(X) hybrid gels (PEGylated polymers), polyethylene oxide (PEO) and chemically modified PEO-(X) hybrid gels, Poly(acrylic acid), 2-hydroxyethyl methacrylate (HEMA)-based polymers and zwitterionic hydrogels such as phosphobetaine, sulfobetaine, and carboxybetaine which can display variable surface activity based on environmental pH. Furthermore, natural or artificial protein layers can be provided to the lumen surface or the hydrogel network and can have specific cellular stabilizing activities. Such a protein layer can include cytokines. Such polymers and proteins can be attached in cross-linked networks or in “brushy” layers of polymer strands. Methodology includes self-assembled monolayers of short chain hydrogels or peptides attached to the inner surface of the lumen of the catheter using a variety of covalent or ionic bonding chemistry and layer-by-layer self-assembly of tailored functionality nano-composite gels.
- In accord with another aspect of the anti-reflux infusion catheter, an alternative or additional coating or structure can be provided to the hub and/or inner lining of the lumen of the catheter that will reduce the wall shear stress during delivery of the immunotherapy. Such a coating or structure can include a hydrophilic coating, a hydrophobic coating, or a small ‘brushy’ fibrous layer that acts to create a region of low flow or no flow along the wall of the catheter. By way of example, the coating can include glycocalyx or a glycocalyx-mimicking layer. Glycocalyx is a glycoprotein-polysaccharide, including several carbohydrate moieties of membrane glycolipids and glycoproteins. In the vascular endothelial tissue, the glycocalyx is a small, irregularly shaped layer extending approximately 50-100 nm into the lumen of a blood vessel, but can be up to 11 μm thick. The coating in the lumen can mimic such biological structure.
- In accord with another aspect of the anti-reflux infusion catheter, wall shear stress along the lumen can be modified by incorporating a surfactant coating 230 b into the lining of the lumen of the catheter. By way of another example, the wall shear stress can be modified by extruding the lumen 208 b of the catheter 204 b with features, including elongate channels 234 b formed along length and open to the central lumen 208 b (
FIG. 6 ). Such channels 234 b are either smaller or bigger than the diameter of a T-cell (e.g., less than 7 microns across or greater than 20 microns across) so as to prevent the channels from engaging and filling with captured T-cells. Thus, the channels will fill with fluid, but no T cells, and the peripheral channel-fluid will guide passage and minimize wall shear stress of the T cells through the lumen. - By way of another example, the catheter is negatively charged. In one manner, this can be effected by providing wires or even a braid about the lumen and applying a negative voltage to the wires (with no/negligible current during use); in another manner, the catheter is constructed with a negatively charged polymer. The immunotherapy agent is naturally negatively charge (as T-cells have negative surface charge). Then, the T-cells in the immunotherapy agent are repelled from the lumen surface to thereby reduce the shear stress upon infusion of the immunotherapy agent.
- In accord with another manner of reducing wall shear stress, the wall shear stress can be minimized by incorporating a surfactant into the immunotherapy fluid containing the T cells. The surfactant can be premixed with the immunotherapy agent or mixed at the time of infusion.
- In accord with a preferred procedure for delivering immunotherapy, a modified Seldinger technique is utilized. In the Seldinger technique, which is well-known and will not be described in detail herein, access is provided from the thigh to the femoral artery and a guidewire is advanced to the aorta. The delivery catheter is advanced over the guidewire. Once the delivery catheter is at its intended position, and in accord with the method herein, an anti-reflux infusion catheter is advanced through the delivery catheter and over the guidewire.
- Then the anti-reflux catheter is displaced relative to the delivery catheter to expose the distal end of the anti-reflux catheter. The anti-reflux catheter is deployed.
- Then, the immunotherapy agent, including immunotherapy T-cells, is infused through the catheter and under pressure to the tumor. Infusion is continued until the prescribed dose of immunotherapy is completely infused. This can occur at sub-stasis, at stasis, or beyond stasis. At stasis, the immunotherapy can be infused without any reflux. Further, by either manually inflating the balloon of a balloon catheter to block flow past the balloon in the vessel, or by use of the dynamically adjustable anti-reflux infusion catheter with valve, the immunotherapy can be infused beyond stasis without concern that the immunotherapy will reflux back toward the vessels of non-target tissues and/or organs.
- After the infusion of the immunotherapy agent, the anti-reflux catheter is removed from the patient, and an arterial closure device is used to close the arterial access point for the procedure.
- There have been described and illustrated herein embodiments of apparatus and methods for delivering immunotherapy agents to target tissue. While particular embodiments of the invention have been described, it is not intended that the invention be limited thereto, as it is intended that the invention be as broad in scope as the art will allow and that the specification be read likewise. Particularly, it is intended that various aspects presented with respect to coated and structurally modifying the lining of the lumen described herein can be used either alone, or in combination with one or multiple other aspects. To such extent, it is anticipated that the lumen can include both structural modification and/or multiple coatings to facilitate passage of the immunotherapy with the least negative effect on the T-cells in the therapy. It will therefore be appreciated by those skilled in the art that yet other modifications could be made to the provided invention without deviating from its spirit and scope as claimed.
Claims (10)
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/064,158 US20160287839A1 (en) | 2015-03-31 | 2016-03-08 | Apparatus and Method for Infusing an Immunotherapy Agent to a Solid Tumor for Treatment |
US16/219,738 US11090460B2 (en) | 2015-03-31 | 2018-12-13 | Method for infusing an immunotherapy agent to a solid tumor for treatment |
US17/376,115 US20210338976A1 (en) | 2015-03-31 | 2021-07-14 | Method of delivering a therapeutic agent to a solid tumor for treatment |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562140651P | 2015-03-31 | 2015-03-31 | |
US15/064,158 US20160287839A1 (en) | 2015-03-31 | 2016-03-08 | Apparatus and Method for Infusing an Immunotherapy Agent to a Solid Tumor for Treatment |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/219,738 Division US11090460B2 (en) | 2015-03-31 | 2018-12-13 | Method for infusing an immunotherapy agent to a solid tumor for treatment |
Publications (1)
Publication Number | Publication Date |
---|---|
US20160287839A1 true US20160287839A1 (en) | 2016-10-06 |
Family
ID=57004599
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/064,158 Abandoned US20160287839A1 (en) | 2015-03-31 | 2016-03-08 | Apparatus and Method for Infusing an Immunotherapy Agent to a Solid Tumor for Treatment |
US16/219,738 Active 2036-07-04 US11090460B2 (en) | 2015-03-31 | 2018-12-13 | Method for infusing an immunotherapy agent to a solid tumor for treatment |
US17/376,115 Pending US20210338976A1 (en) | 2015-03-31 | 2021-07-14 | Method of delivering a therapeutic agent to a solid tumor for treatment |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/219,738 Active 2036-07-04 US11090460B2 (en) | 2015-03-31 | 2018-12-13 | Method for infusing an immunotherapy agent to a solid tumor for treatment |
US17/376,115 Pending US20210338976A1 (en) | 2015-03-31 | 2021-07-14 | Method of delivering a therapeutic agent to a solid tumor for treatment |
Country Status (2)
Country | Link |
---|---|
US (3) | US20160287839A1 (en) |
WO (1) | WO2016160446A1 (en) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20160287839A1 (en) * | 2015-03-31 | 2016-10-06 | Surefire Medical, Inc. | Apparatus and Method for Infusing an Immunotherapy Agent to a Solid Tumor for Treatment |
US11877752B2 (en) | 2016-09-07 | 2024-01-23 | Daniel Ezra Walzman | Filterless aspiration, irrigating, macerating, rotating microcatheter and method of use |
US11439492B2 (en) | 2016-09-07 | 2022-09-13 | Daniel Ezra Walzman | Lasso filter tipped microcatheter for simultaneous rotating separator, irrigator for thrombectomy and method for use |
US11400263B1 (en) | 2016-09-19 | 2022-08-02 | Trisalus Life Sciences, Inc. | System and method for selective pressure-controlled therapeutic delivery |
US11850398B2 (en) | 2018-08-01 | 2023-12-26 | Trisalus Life Sciences, Inc. | Systems and methods for pressure-facilitated therapeutic agent delivery |
US20200069913A1 (en) * | 2018-09-05 | 2020-03-05 | Boston Scientific Scimed, Inc. | Aorto ostial fluid directing device |
US11338117B2 (en) | 2018-10-08 | 2022-05-24 | Trisalus Life Sciences, Inc. | Implantable dual pathway therapeutic agent delivery port |
USD977642S1 (en) * | 2018-10-29 | 2023-02-07 | W. L. Gore & Associates, Inc. | Pulmonary valve conduit |
JP2023542989A (en) | 2020-09-22 | 2023-10-12 | トリサルース・ライフ・サイエンシズ・インコーポレイテッド | Cancer treatment using toll-like receptor agonists |
US20230364125A1 (en) | 2020-09-22 | 2023-11-16 | Trisalus Life Sciences, Inc. | Cancer therapy using toll-like receptor agonists |
KR20240004419A (en) | 2021-04-01 | 2024-01-11 | 트라이살루스 라이프 사이언시즈, 인크. | Cancer therapy using toll-like receptor agonists |
EP4329890A1 (en) | 2021-04-29 | 2024-03-06 | TriSalus Life Sciences, Inc. | Cancer therapy using checkpoint inhibitors |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040220511A1 (en) * | 2003-04-29 | 2004-11-04 | Neal Scott | Polymer coated device for electrically mediated drug delivery |
US20120116351A1 (en) * | 2009-12-02 | 2012-05-10 | Chomas James E | Method of Operating a Microvalve Protection Device |
US20140378951A1 (en) * | 2013-06-20 | 2014-12-25 | Philip J. Dye | Catheter |
Family Cites Families (244)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US926591A (en) | 1906-09-04 | 1909-06-29 | Torris Wold & Company | Double seamer. |
DE2821048C2 (en) | 1978-05-13 | 1980-07-17 | Willy Ruesch Gmbh & Co Kg, 7053 Kernen | Medical instrument |
US4261341A (en) | 1979-06-08 | 1981-04-14 | Hakim Company Limited | Method and apparatus for the treatment of ascites |
US4311587A (en) | 1979-12-10 | 1982-01-19 | Japan Foundation For Artificial Organs | Filter arrangement denying bacteria entry to peritoneum |
SE445884B (en) | 1982-04-30 | 1986-07-28 | Medinvent Sa | DEVICE FOR IMPLANTATION OF A RODFORM PROTECTION |
US4883459A (en) | 1983-07-29 | 1989-11-28 | Reynaldo Calderon | Retrograde perfusion |
US4714460A (en) | 1983-07-29 | 1987-12-22 | Reynaldo Calderon | Methods and systems for retrograde perfusion in the body for curing it of the disease or immume deficiency |
US4840542A (en) | 1985-03-27 | 1989-06-20 | Quest Medical, Inc. | Infusion pump with direct pressure sensing |
US4738740A (en) | 1985-11-21 | 1988-04-19 | Corvita Corporation | Method of forming implantable vascular grafts |
US4800016A (en) | 1986-11-24 | 1989-01-24 | The University Of Michigan | Extracorporeal blood de-heparinization system |
US4892518A (en) | 1987-12-04 | 1990-01-09 | Biocontrol Technology, Inc. | Hemodialysis |
WO1989011309A1 (en) | 1988-05-16 | 1989-11-30 | Terumo Kabushiki Kaisha | Subcutaneously implanted catheter assembly |
US5234425A (en) | 1989-03-03 | 1993-08-10 | Thomas J. Fogarty | Variable diameter sheath method and apparatus for use in body passages |
DE8910603U1 (en) | 1989-09-06 | 1989-12-07 | Guenther, Rolf W., Prof. Dr. | |
US5034001A (en) | 1989-09-08 | 1991-07-23 | Advanced Cardiovascular Systems, Inc. | Method of repairing a damaged blood vessel with an expandable cage catheter |
FR2652267B1 (en) | 1989-09-27 | 1997-12-12 | Prothia Sarl | CATHETER DEVICE AND FILTER FOR CELLAR VEIN. |
US5030199A (en) | 1989-12-11 | 1991-07-09 | Medical Engineering Corporation | Female incontinence control device with magnetically operable valve and method |
US5071407A (en) | 1990-04-12 | 1991-12-10 | Schneider (U.S.A.) Inc. | Radially expandable fixation member |
US5221261A (en) | 1990-04-12 | 1993-06-22 | Schneider (Usa) Inc. | Radially expandable fixation member |
DE9109006U1 (en) | 1991-07-22 | 1991-10-10 | Schmitz-Rode, Thomas, Dipl.-Ing. Dr.Med., 5100 Aachen, De | |
DE59205857D1 (en) | 1992-02-03 | 1996-05-02 | Schneider Europ Ag | Catheter with a stent |
US5484399A (en) * | 1992-02-27 | 1996-01-16 | Sloan-Kettering Institute For Cancer Research | Process and device to reduce interstitial fluid pressure in tissue |
FR2688401B1 (en) | 1992-03-12 | 1998-02-27 | Thierry Richard | EXPANDABLE STENT FOR HUMAN OR ANIMAL TUBULAR MEMBER, AND IMPLEMENTATION TOOL. |
FR2692275A1 (en) | 1992-06-10 | 1993-12-17 | Du Pont | New lacquer based on silicon and zirconium, its use as a substrate coating and the substrates thus obtained. |
US5897567A (en) | 1993-04-29 | 1999-04-27 | Scimed Life Systems, Inc. | Expandable intravascular occlusion material removal devices and methods of use |
US5411478A (en) | 1993-07-12 | 1995-05-02 | Michael E. Stillabower | Angioplasty apparatus and process |
US5397307A (en) | 1993-12-07 | 1995-03-14 | Schneider (Usa) Inc. | Drug delivery PTCA catheter and method for drug delivery |
US5419763B1 (en) | 1994-01-04 | 1997-07-15 | Cor Trak Medical Inc | Prostatic drug-delivery catheter |
US5759205A (en) | 1994-01-21 | 1998-06-02 | Brown University Research Foundation | Negatively charged polymeric electret implant |
US5484412A (en) | 1994-04-19 | 1996-01-16 | Pierpont; Brien E. | Angioplasty method and means for performing angioplasty |
US5836905A (en) | 1994-06-20 | 1998-11-17 | Lemelson; Jerome H. | Apparatus and methods for gene therapy |
US5899882A (en) | 1994-10-27 | 1999-05-04 | Novoste Corporation | Catheter apparatus for radiation treatment of a desired area in the vascular system of a patient |
US5688237A (en) | 1995-05-04 | 1997-11-18 | Cedars-Sinai Medical Center | Implantable catheter and method of use |
US5895398A (en) | 1996-02-02 | 1999-04-20 | The Regents Of The University Of California | Method of using a clot capture coil |
US5810789A (en) | 1996-04-05 | 1998-09-22 | C. R. Bard, Inc. | Catheters with novel lumen shapes |
WO1997042879A1 (en) | 1996-05-14 | 1997-11-20 | Embol-X, Inc. | Aortic occluder with associated filter and methods of use during cardiac surgery |
US5662671A (en) | 1996-07-17 | 1997-09-02 | Embol-X, Inc. | Atherectomy device having trapping and excising means for removal of plaque from the aorta and other arteries |
US5957974A (en) | 1997-01-23 | 1999-09-28 | Schneider (Usa) Inc | Stent graft with braided polymeric sleeve |
US5893869A (en) | 1997-02-19 | 1999-04-13 | University Of Iowa Research Foundation | Retrievable inferior vena cava filter system and method for use thereof |
US5814064A (en) | 1997-03-06 | 1998-09-29 | Scimed Life Systems, Inc. | Distal protection device |
US6152946A (en) | 1998-03-05 | 2000-11-28 | Scimed Life Systems, Inc. | Distal protection device and method |
US6974469B2 (en) | 1997-03-06 | 2005-12-13 | Scimed Life Systems, Inc. | Distal protection device and method |
US6676682B1 (en) | 1997-05-08 | 2004-01-13 | Scimed Life Systems, Inc. | Percutaneous catheter and guidewire having filter and medical device deployment capabilities |
US5911734A (en) | 1997-05-08 | 1999-06-15 | Embol-X, Inc. | Percutaneous catheter and guidewire having filter and medical device deployment capabilities |
US6258120B1 (en) | 1997-12-23 | 2001-07-10 | Embol-X, Inc. | Implantable cerebral protection device and methods of use |
US6059745A (en) | 1997-05-20 | 2000-05-09 | Gelbfish; Gary A. | Thrombectomy device and associated method |
EP0893138B1 (en) | 1997-06-23 | 2004-05-26 | Schneider (Europe) GmbH | Catheter assembly |
US20010041862A1 (en) | 1997-09-02 | 2001-11-15 | Morton G. Glickman | Novel apparatus and method of treating a tumor in the extremity of a patient |
US6361545B1 (en) | 1997-09-26 | 2002-03-26 | Cardeon Corporation | Perfusion filter catheter |
US6395014B1 (en) | 1997-09-26 | 2002-05-28 | John A. Macoviak | Cerebral embolic protection assembly and associated methods |
CA2309055C (en) | 1997-11-07 | 2004-08-03 | Salviac Limited | An embolic protection device |
US20040260333A1 (en) | 1997-11-12 | 2004-12-23 | Dubrul William R. | Medical device and method |
US6764461B2 (en) | 1997-12-01 | 2004-07-20 | Scimed Life Systems, Inc. | Catheter system for the delivery of a low volume bolus |
US6699231B1 (en) | 1997-12-31 | 2004-03-02 | Heartport, Inc. | Methods and apparatus for perfusion of isolated tissue structure |
JP2002502626A (en) | 1998-02-10 | 2002-01-29 | アーテミス・メディカル・インコーポレイテッド | Supplementary device and method of using the same |
EP1061856A1 (en) | 1998-03-04 | 2000-12-27 | Bioguide Consulting, Inc. | Guidewire filter device |
AU748342B2 (en) | 1998-03-09 | 2002-06-06 | Avent, Inc. | Tracheal breathing apparatus |
US6582396B1 (en) | 1998-05-13 | 2003-06-24 | Arteria Medical Science, Inc. | Puncture resistant balloon for use in carotid artery procedures and methods of use |
US6936060B2 (en) | 1998-05-13 | 2005-08-30 | Arteria Medical Sciences, Inc. | Apparatus and methods for removing emboli during a surgical procedure |
US6645222B1 (en) | 1998-05-13 | 2003-11-11 | Arteria Medical Science, Inc. | Puncture resistant branch artery occlusion device and methods of use |
US6908474B2 (en) | 1998-05-13 | 2005-06-21 | Gore Enterprise Holdings, Inc. | Apparatus and methods for reducing embolization during treatment of carotid artery disease |
DE69928924T2 (en) | 1998-05-21 | 2006-09-28 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | CANNULA FOR THE SELECTIVE PRESSURE-DEPENDENT ADMINISTRATION OF THERAPEUTIC SUBSTANCES |
US6306163B1 (en) | 1998-08-04 | 2001-10-23 | Advanced Cardiovascular Systems, Inc. | Assembly for collecting emboli and method of use |
US7118600B2 (en) | 1998-08-31 | 2006-10-10 | Wilson-Cook Medical, Inc. | Prosthesis having a sleeve valve |
US6746489B2 (en) | 1998-08-31 | 2004-06-08 | Wilson-Cook Medical Incorporated | Prosthesis having a sleeve valve |
US6051014A (en) | 1998-10-13 | 2000-04-18 | Embol-X, Inc. | Percutaneous filtration catheter for valve repair surgery and methods of use |
US6165199A (en) | 1999-01-12 | 2000-12-26 | Coaxia, Inc. | Medical device for removing thromboembolic material from cerebral arteries and methods of use |
US6896690B1 (en) | 2000-01-27 | 2005-05-24 | Viacor, Inc. | Cardiac valve procedure methods and devices |
US6231551B1 (en) | 1999-03-01 | 2001-05-15 | Coaxia, Inc. | Partial aortic occlusion devices and methods for cerebral perfusion augmentation |
US6743196B2 (en) | 1999-03-01 | 2004-06-01 | Coaxia, Inc. | Partial aortic occlusion devices and methods for cerebral perfusion augmentation |
AU5595300A (en) | 1999-06-02 | 2000-12-18 | Microheart, Inc. | Devices and methods for delivering a drug |
US6339718B1 (en) | 1999-07-30 | 2002-01-15 | Medrad, Inc. | Programmable injector control |
US6168579B1 (en) | 1999-08-04 | 2001-01-02 | Scimed Life Systems, Inc. | Filter flush system and methods of use |
US6235044B1 (en) | 1999-08-04 | 2001-05-22 | Scimed Life Systems, Inc. | Percutaneous catheter and guidewire for filtering during ablation of mycardial or vascular tissue |
US6652555B1 (en) | 1999-10-27 | 2003-11-25 | Atritech, Inc. | Barrier device for covering the ostium of left atrial appendage |
US6551303B1 (en) | 1999-10-27 | 2003-04-22 | Atritech, Inc. | Barrier device for ostium of left atrial appendage |
US6689150B1 (en) | 1999-10-27 | 2004-02-10 | Atritech, Inc. | Filter apparatus for ostium of left atrial appendage |
US6371971B1 (en) | 1999-11-15 | 2002-04-16 | Scimed Life Systems, Inc. | Guidewire filter and methods of use |
GB9928905D0 (en) | 1999-12-08 | 2000-02-02 | Aortech Europ Ltd | Prosthesis |
US6660021B1 (en) | 1999-12-23 | 2003-12-09 | Advanced Cardiovascular Systems, Inc. | Intravascular device and system |
WO2001045592A1 (en) | 1999-12-23 | 2001-06-28 | Percusurge, Inc. | Vascular filters with radiopaque markings |
US6383206B1 (en) | 1999-12-30 | 2002-05-07 | Advanced Cardiovascular Systems, Inc. | Embolic protection system and method including filtering elements |
US6540722B1 (en) | 1999-12-30 | 2003-04-01 | Advanced Cardiovascular Systems, Inc. | Embolic protection devices |
US6702834B1 (en) | 1999-12-30 | 2004-03-09 | Advanced Cardiovascular Systems, Inc. | Embolic protection devices |
US6645220B1 (en) | 1999-12-30 | 2003-11-11 | Advanced Cardiovascular Systems, Inc. | Embolic protection system and method including and embolic-capturing filter |
US6695813B1 (en) | 1999-12-30 | 2004-02-24 | Advanced Cardiovascular Systems, Inc. | Embolic protection devices |
US6663613B1 (en) | 2000-01-25 | 2003-12-16 | Bacchus Vascular, Inc. | System and methods for clot dissolution |
US7749245B2 (en) | 2000-01-27 | 2010-07-06 | Medtronic, Inc. | Cardiac valve procedure methods and devices |
US7322957B2 (en) | 2000-02-01 | 2008-01-29 | Harold D. Kletschka | Angioplasty device and method of making same |
US6443926B1 (en) | 2000-02-01 | 2002-09-03 | Harold D. Kletschka | Embolic protection device having expandable trap |
EP1253871B1 (en) | 2000-03-10 | 2007-02-14 | Anthony T. Don Michael | Vascular embolism preventon device employing filters |
GB2369575A (en) | 2000-04-20 | 2002-06-05 | Salviac Ltd | An embolic protection system |
US6706053B1 (en) | 2000-04-28 | 2004-03-16 | Advanced Cardiovascular Systems, Inc. | Nitinol alloy design for sheath deployable and re-sheathable vascular devices |
US6890315B1 (en) | 2000-05-23 | 2005-05-10 | Chf Solutions, Inc. | Method and apparatus for vein fluid removal in heart failure |
US6478783B1 (en) | 2000-05-26 | 2002-11-12 | H. Robert Moorehead | Anti-sludge medication ports and related methods |
US8435225B2 (en) | 2000-06-02 | 2013-05-07 | Fox Hollow Technologies, Inc. | Embolization protection system for vascular procedures |
US6939362B2 (en) | 2001-11-27 | 2005-09-06 | Advanced Cardiovascular Systems, Inc. | Offset proximal cage for embolic filtering devices |
AU2000260532A1 (en) | 2000-06-20 | 2002-01-02 | CHF Soultions, Inc | Apparatus and method for perfusing the kidney with venous blood |
WO2002005888A1 (en) | 2000-06-30 | 2002-01-24 | Viacor Incorporated | Intravascular filter with debris entrapment mechanism |
US6685672B1 (en) | 2000-07-13 | 2004-02-03 | Edwards Lifesciences Corporation | Multi-balloon drug delivery catheter for angiogenesis |
US6964670B1 (en) | 2000-07-13 | 2005-11-15 | Advanced Cardiovascular Systems, Inc. | Embolic protection guide wire |
US6855154B2 (en) | 2000-08-11 | 2005-02-15 | University Of Louisville Research Foundation, Inc. | Endovascular aneurysm treatment device and method |
US6569146B1 (en) | 2000-08-18 | 2003-05-27 | Scimed Life Systems, Inc. | Method and apparatus for treating saphenous vein graft lesions |
IL155015A0 (en) | 2000-09-21 | 2003-10-31 | Atritech Inc | Apparatus for implanting devices in atrial appendages |
US6416495B1 (en) | 2000-10-10 | 2002-07-09 | Science Incorporated | Implantable fluid delivery device for basal and bolus delivery of medicinal fluids |
US6537294B1 (en) | 2000-10-17 | 2003-03-25 | Advanced Cardiovascular Systems, Inc. | Delivery systems for embolic filter devices |
WO2002056796A1 (en) | 2000-12-01 | 2002-07-25 | Nephros Therapeutics, Inc. | Intravascular blood conditioning device and use thereof |
US20020128680A1 (en) | 2001-01-25 | 2002-09-12 | Pavlovic Jennifer L. | Distal protection device with electrospun polymer fiber matrix |
US7226464B2 (en) | 2001-03-01 | 2007-06-05 | Scimed Life Systems, Inc. | Intravascular filter retrieval device having an actuatable dilator tip |
US7214237B2 (en) | 2001-03-12 | 2007-05-08 | Don Michael T Anthony | Vascular filter with improved strength and flexibility |
US6911036B2 (en) | 2001-04-03 | 2005-06-28 | Medtronic Vascular, Inc. | Guidewire apparatus for temporary distal embolic protection |
US6706055B2 (en) | 2001-04-03 | 2004-03-16 | Medtronic Ave Inc. | Guidewire apparatus for temporary distal embolic protection |
US7044958B2 (en) | 2001-04-03 | 2006-05-16 | Medtronic Vascular, Inc. | Temporary device for capturing embolic material |
US6818006B2 (en) | 2001-04-03 | 2004-11-16 | Medtronic Vascular, Inc. | Temporary intraluminal filter guidewire |
US6866677B2 (en) | 2001-04-03 | 2005-03-15 | Medtronic Ave, Inc. | Temporary intraluminal filter guidewire and methods of use |
US6645223B2 (en) | 2001-04-30 | 2003-11-11 | Advanced Cardiovascular Systems, Inc. | Deployment and recovery control systems for embolic protection devices |
US6746469B2 (en) | 2001-04-30 | 2004-06-08 | Advanced Cardiovascular Systems, Inc. | Balloon actuated apparatus having multiple embolic filters, and method of use |
US6830579B2 (en) | 2001-05-01 | 2004-12-14 | Coaxia, Inc. | Devices and methods for preventing distal embolization using flow reversal and perfusion augmentation within the cerebral vasculature |
US6635070B2 (en) | 2001-05-21 | 2003-10-21 | Bacchus Vascular, Inc. | Apparatus and methods for capturing particulate material within blood vessels |
US6520183B2 (en) | 2001-06-11 | 2003-02-18 | Memorial Sloan-Kettering Cancer Center | Double endobronchial catheter for one lung isolation anesthesia and surgery |
US7338510B2 (en) | 2001-06-29 | 2008-03-04 | Advanced Cardiovascular Systems, Inc. | Variable thickness embolic filtering devices and method of manufacturing the same |
US6533800B1 (en) | 2001-07-25 | 2003-03-18 | Coaxia, Inc. | Devices and methods for preventing distal embolization using flow reversal in arteries having collateral blood flow |
US6902540B2 (en) | 2001-08-22 | 2005-06-07 | Gerald Dorros | Apparatus and methods for treating stroke and controlling cerebral flow characteristics |
US6656351B2 (en) | 2001-08-31 | 2003-12-02 | Advanced Cardiovascular Systems, Inc. | Embolic protection devices one way porous membrane |
US9242069B2 (en) | 2001-09-30 | 2016-01-26 | Scicotec Gmbh | Method for control of stem cell injection into the body |
US8980568B2 (en) * | 2001-10-11 | 2015-03-17 | Aviva Biosciences Corporation | Methods and compositions for detecting non-hematopoietic cells from a blood sample |
CA2463415C (en) | 2001-10-25 | 2012-02-07 | Emory University | Catheter for modified perfusion |
US6755813B2 (en) | 2001-11-20 | 2004-06-29 | Cleveland Clinic Foundation | Apparatus and method for performing thrombolysis |
US6837898B2 (en) | 2001-11-30 | 2005-01-04 | Advanced Cardiovascular Systems, Inc. | Intraluminal delivery system for an attachable treatment device |
ES2399091T3 (en) | 2001-12-05 | 2013-03-25 | Keystone Heart Ltd. | Endovascular device for entrapment of particulate matter and method of use |
US7241304B2 (en) | 2001-12-21 | 2007-07-10 | Advanced Cardiovascular Systems, Inc. | Flexible and conformable embolic filtering devices |
US20030125790A1 (en) | 2001-12-27 | 2003-07-03 | Vitaly Fastovsky | Deployment device, system and method for medical implantation |
US6641572B2 (en) | 2002-01-24 | 2003-11-04 | Michael Cherkassky | Interstitial space saturation |
US7344549B2 (en) | 2002-01-31 | 2008-03-18 | Advanced Cardiovascular Systems, Inc. | Expandable cages for embolic filtering devices |
US8062251B2 (en) | 2002-02-01 | 2011-11-22 | Vascular Designs, Inc. | Multi-function catheter and use thereof |
US7653438B2 (en) | 2002-04-08 | 2010-01-26 | Ardian, Inc. | Methods and apparatus for renal neuromodulation |
US7853333B2 (en) | 2002-04-08 | 2010-12-14 | Ardian, Inc. | Methods and apparatus for multi-vessel renal neuromodulation |
SE0201053D0 (en) | 2002-04-08 | 2002-04-08 | Corline Systems Ab | Stent assembly and device for application thereof |
US7162303B2 (en) | 2002-04-08 | 2007-01-09 | Ardian, Inc. | Renal nerve stimulation method and apparatus for treatment of patients |
US7620451B2 (en) | 2005-12-29 | 2009-11-17 | Ardian, Inc. | Methods and apparatus for pulsed electric field neuromodulation via an intra-to-extravascular approach |
AU2003223749A1 (en) | 2002-04-25 | 2003-11-10 | The Board Of Trustees Of The Leland Stanford Junior University | Expandable guide sheath and apparatus and methods using such sheaths |
US7503904B2 (en) | 2002-04-25 | 2009-03-17 | Cardiac Pacemakers, Inc. | Dual balloon telescoping guiding catheter |
US7585309B2 (en) | 2002-05-16 | 2009-09-08 | Boston Scientific Scimed, Inc. | Aortic filter |
US6887258B2 (en) | 2002-06-26 | 2005-05-03 | Advanced Cardiovascular Systems, Inc. | Embolic filtering devices for bifurcated vessels |
US7172614B2 (en) | 2002-06-27 | 2007-02-06 | Advanced Cardiovascular Systems, Inc. | Support structures for embolic filtering devices |
US7232452B2 (en) | 2002-07-12 | 2007-06-19 | Ev3 Inc. | Device to create proximal stasis |
US7223253B2 (en) | 2002-07-29 | 2007-05-29 | Gore Enterprise Holdings, Inc. | Blood aspiration system and methods of use |
EP1585572A4 (en) | 2002-09-20 | 2010-02-24 | Flowmedica Inc | Method and apparatus for intra aortic substance delivery to a branch vessel |
US7331973B2 (en) | 2002-09-30 | 2008-02-19 | Avdanced Cardiovascular Systems, Inc. | Guide wire with embolic filtering attachment |
US7252675B2 (en) | 2002-09-30 | 2007-08-07 | Advanced Cardiovascular, Inc. | Embolic filtering devices |
US20040064030A1 (en) | 2002-10-01 | 2004-04-01 | Peter Forsell | Detection of implanted injection port |
WO2004043293A2 (en) | 2002-11-13 | 2004-05-27 | Viacor, Inc. | Cardiac valve procedure methods and devices |
EP1572287B1 (en) | 2002-12-02 | 2011-02-23 | Med-El Elektromedizinische Geräte GmbH | Fluid switch controlled trans-cutaneously via a magnetic force |
DE10261575A1 (en) | 2002-12-23 | 2004-07-08 | Nova Lung Gmbh | Device for cannulating a blood-carrying vessel and its use for cannulating blood-carrying vessels |
US7658747B2 (en) | 2003-03-12 | 2010-02-09 | Nmt Medical, Inc. | Medical device for manipulation of a medical implant |
US20050015048A1 (en) | 2003-03-12 | 2005-01-20 | Chiu Jessica G. | Infusion treatment agents, catheters, filter devices, and occlusion devices, and use thereof |
US7250041B2 (en) | 2003-03-12 | 2007-07-31 | Abbott Cardiovascular Systems Inc. | Retrograde pressure regulated infusion |
US7591832B2 (en) | 2003-04-24 | 2009-09-22 | Medtronic, Inc. | Expandable guide sheath and apparatus with distal protection and methods for use |
US7655022B2 (en) | 2003-04-28 | 2010-02-02 | Cardiac Pacemakers, Inc. | Compliant guiding catheter sheath system |
DE602004023350D1 (en) | 2003-04-30 | 2009-11-12 | Medtronic Vascular Inc | Percutaneous inserted provisional valve |
US7537600B2 (en) | 2003-06-12 | 2009-05-26 | Boston Scientific Scimed, Inc. | Valved embolic protection filter |
US7842084B2 (en) | 2005-06-21 | 2010-11-30 | 3F Therapeutics, Inc. | Method and systems for sizing, folding, holding, and delivering a heart valve prosthesis |
US7604650B2 (en) | 2003-10-06 | 2009-10-20 | 3F Therapeutics, Inc. | Method and assembly for distal embolic protection |
US20050075713A1 (en) | 2003-10-06 | 2005-04-07 | Brian Biancucci | Minimally invasive valve replacement system |
US6994718B2 (en) | 2003-10-29 | 2006-02-07 | Medtronic Vascular, Inc. | Distal protection device for filtering and occlusion |
EP1740219B1 (en) * | 2004-04-30 | 2015-03-04 | OrbusNeich Medical, Inc. | Medical device with coating for capturing genetically-altered cells and methods of using same |
US7544202B2 (en) | 2004-06-25 | 2009-06-09 | Angiodynamics, Inc. | Retrievable blood clot filter |
US7172621B2 (en) | 2004-09-24 | 2007-02-06 | Laurence Theron | Method of performing protected angioplasty and stenting at a carotid bifurcation |
US7279000B2 (en) | 2004-09-29 | 2007-10-09 | Angiodynamics Inc | Permanent blood clot filter with capability of being retrieved |
CA2583308C (en) | 2004-10-08 | 2020-01-07 | Georgia Tech Research Corporation | Microencapsulation of cells in hydrogels using electrostatic potentials |
US7309324B2 (en) | 2004-10-15 | 2007-12-18 | Futuremed Interventional, Inc. | Non-compliant medical balloon having an integral woven fabric layer |
US7937143B2 (en) | 2004-11-02 | 2011-05-03 | Ardian, Inc. | Methods and apparatus for inducing controlled renal neuromodulation |
US20080021497A1 (en) | 2005-01-03 | 2008-01-24 | Eric Johnson | Endoluminal filter |
US20060173490A1 (en) | 2005-02-01 | 2006-08-03 | Boston Scientific Scimed, Inc. | Filter system and method |
US7935075B2 (en) | 2005-04-26 | 2011-05-03 | Cardiac Pacemakers, Inc. | Self-deploying vascular occlusion device |
EP2308547B1 (en) | 2005-04-27 | 2014-09-17 | C.R. Bard, Inc. | High pressure access port with septum |
EP1743524A1 (en) | 2005-07-13 | 2007-01-17 | ID-Lelystad, Instituut voor Dierhouderij en Diergezondheid B.V. | An animal model for type II diabetes mellitus and syndrome x |
US9974887B2 (en) * | 2005-10-04 | 2018-05-22 | Clph, Llc | Catheters with lubricious linings and methods for making and using them |
US7837702B2 (en) | 2005-12-21 | 2010-11-23 | Nexeon Medsystems, Inc. | Interventional catheter for retrograde use having embolic protection capability and methods of use |
US8172792B2 (en) | 2005-12-27 | 2012-05-08 | Tyco Healthcare Group Lp | Embolic protection systems for bifurcated conduits |
WO2007079153A2 (en) | 2005-12-29 | 2007-07-12 | Wilson-Cook Medical Inc. | A hybrid intraluminal device with varying expansion force |
US20070156223A1 (en) | 2005-12-30 | 2007-07-05 | Dennis Vaughan | Stent delivery system with improved delivery force distribution |
WO2007109164A2 (en) | 2006-03-20 | 2007-09-27 | Medical Components, Inc. | Venous access port assembly and methods of assembly and use |
WO2007110864A2 (en) | 2006-03-27 | 2007-10-04 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Intraluminal mass collector |
ATE494040T1 (en) | 2006-06-28 | 2011-01-15 | Ardian Inc | SYSTEMS FOR HEAT-INDUCED RENAL NEUROMODULATION |
JP4924235B2 (en) | 2006-08-01 | 2012-04-25 | セイコーエプソン株式会社 | Fluid transport system, fluid transport device |
US20080033341A1 (en) | 2006-08-04 | 2008-02-07 | Bay Holdings Ltd. | Methods and devices for reducing or blocking blood flow to a selected blood vessel or part thereof |
US7938799B2 (en) | 2006-08-10 | 2011-05-10 | Boston Scientific Scimed, Inc. | Medical device for vessel compatibility during high pressure infusion |
WO2008024434A1 (en) | 2006-08-24 | 2008-02-28 | Fresenius Medical Care Holdings, Inc. | Device for removing fluid from blood in a patient |
US8200312B2 (en) | 2006-09-06 | 2012-06-12 | Yeda Research And Development Co. Ltd. | Apparatus for monitoring a system pressure in space with time and method for assessing drug delivery and resistance to therapy and product |
EP3827841B1 (en) * | 2006-10-09 | 2024-04-03 | Neurofluidics, Inc. | Cerebrospinal fluid purification system |
US20080147007A1 (en) | 2006-12-19 | 2008-06-19 | Toby Freyman | Delivery device with pressure control |
US9144509B2 (en) * | 2007-05-31 | 2015-09-29 | Abbott Cardiovascular Systems Inc. | Method and apparatus for delivering an agent to a kidney |
JP2009034462A (en) | 2007-07-31 | 2009-02-19 | Koosei Advance:Kk | Perfusion system for therapy of pancreas |
EP2195068B1 (en) | 2007-09-12 | 2017-07-26 | Cook Medical Technologies LLC | Balloon catheter for delivering a therapeutic agent |
EP2211936B1 (en) | 2007-11-07 | 2014-07-16 | LANE, Rodney James | Systems and devices for circulatory access |
WO2009099935A2 (en) * | 2008-02-01 | 2009-08-13 | Boston Scientific Scimed, Inc. | Drug-coated medical devices for differential drug release |
US8192675B2 (en) | 2008-03-13 | 2012-06-05 | Cook Medical Technologies Llc | Cutting balloon with connector and dilation element |
EP2110151A1 (en) | 2008-04-16 | 2009-10-21 | Edward Diethrich | Double balloon occlusion device |
AU2009270849B2 (en) * | 2008-07-17 | 2013-11-21 | Micell Technologies, Inc. | Drug delivery medical device |
US8162879B2 (en) | 2008-09-22 | 2012-04-24 | Tyco Healthcare Group Lp | Double balloon catheter and methods for homogeneous drug delivery using the same |
BRPI0919884B8 (en) | 2008-11-03 | 2023-04-04 | Atlanta Catheter Therapies Inc | occlusion perfusion catheter |
US8540667B2 (en) * | 2008-11-12 | 2013-09-24 | Sanovas, Inc. | Multi-balloon catheter for extravasated drug delivery |
US11045300B2 (en) | 2008-12-19 | 2021-06-29 | Cvdevices, Llc | Systems, devices, and methods for organ retroperfusion along with regional mild hypothermia |
US8388644B2 (en) | 2008-12-29 | 2013-03-05 | Cook Medical Technologies Llc | Embolic protection device and method of use |
US9675673B2 (en) | 2009-04-24 | 2017-06-13 | Ingeneron Incorporated | Transluminal delivery of oncoltyic viruses for cancer therapy |
WO2010135352A1 (en) | 2009-05-18 | 2010-11-25 | Pneumrx, Inc. | Cross-sectional modification during deployment of an elongate lung volume reduction device |
US20110092955A1 (en) | 2009-10-07 | 2011-04-21 | Purdy Phillip D | Pressure-Sensing Medical Devices, Systems and Methods, and Methods of Forming Medical Devices |
US10512761B2 (en) | 2009-12-02 | 2019-12-24 | Renovorx, Inc. | Methods for delivery of therapeutic materials to treat pancreatic cancer |
US8500775B2 (en) | 2009-12-02 | 2013-08-06 | Surefire Medical, Inc. | Protection device and method against embolization agent reflux |
US9457171B2 (en) | 2009-12-02 | 2016-10-04 | Renovorx, Inc. | Devices, methods and kits for delivery of therapeutic materials to a target artery |
US8696698B2 (en) * | 2009-12-02 | 2014-04-15 | Surefire Medical, Inc. | Microvalve protection device and method of use for protection against embolization agent reflux |
EP2506913B8 (en) | 2009-12-02 | 2020-11-18 | RenovoRX, Inc. | Devices and kits for delivery of therapeutic materials to a pancreas |
US20160082178A1 (en) | 2009-12-02 | 2016-03-24 | Renovorx, Inc. | Angiographic methods for identification of feeder vessels |
WO2011112463A1 (en) | 2010-03-06 | 2011-09-15 | Fulton Richard Eustis Iii | Recovery catheter assembly |
US9126016B2 (en) | 2010-05-19 | 2015-09-08 | Nfusion Vascular Systems Llc | Augmented delivery catheter and method |
US8397578B2 (en) | 2010-06-03 | 2013-03-19 | Medtronic, Inc. | Capacitive pressure sensor assembly |
JP6160000B2 (en) | 2010-10-01 | 2017-07-12 | ヴァリアン メディカル システムズ インコーポレイテッド | Delivery catheter for delivering grafts, for example for bronchoscopic implantation of markers in the lung |
US9770319B2 (en) | 2010-12-01 | 2017-09-26 | Surefire Medical, Inc. | Closed tip dynamic microvalve protection device |
US9061117B2 (en) | 2011-04-08 | 2015-06-23 | John R. Roberts | Catheter systems and methods of use |
US9089668B2 (en) | 2011-09-28 | 2015-07-28 | Surefire Medical, Inc. | Flow directional infusion device |
US9730726B2 (en) | 2011-10-07 | 2017-08-15 | W. L. Gore & Associates, Inc. | Balloon assemblies having controllably variable topographies |
US9089341B2 (en) | 2012-02-28 | 2015-07-28 | Surefire Medical, Inc. | Renal nerve neuromodulation device |
US9604037B2 (en) | 2012-06-05 | 2017-03-28 | Muffin Incorporated | Catheter systems and methods useful for cell therapy |
US9364358B2 (en) | 2012-07-27 | 2016-06-14 | Medinol Ltd. | Catheter with retractable cover and pressurized fluid |
US9486573B2 (en) | 2013-03-14 | 2016-11-08 | Bayer Healthcare Llc | Fluid delivery system and method of fluid delivery to a patient |
WO2014182959A2 (en) | 2013-05-08 | 2014-11-13 | Embolx, Inc. | Device and methods for transvascular tumor embolization with integrated flow regulation |
US9844383B2 (en) | 2013-05-08 | 2017-12-19 | Embolx, Inc. | Devices and methods for low pressure tumor embolization |
WO2014197362A1 (en) | 2013-06-03 | 2014-12-11 | Ramtin Agah | Devices, methods and kits for delivery of therapeutic materials to a pancreas |
JP5992385B2 (en) | 2013-10-02 | 2016-09-14 | 村田 智 | Pancreatic perfusion apparatus and control method thereof |
US9968740B2 (en) | 2014-03-25 | 2018-05-15 | Surefire Medical, Inc. | Closed tip dynamic microvalve protection device |
EP2995335B1 (en) * | 2014-09-11 | 2022-10-12 | Pine Medical Limited | Drug coated balloon catheter and method of manufacture thereof |
US10092742B2 (en) | 2014-09-22 | 2018-10-09 | Ekos Corporation | Catheter system |
US11147946B2 (en) | 2014-10-03 | 2021-10-19 | The Regents Of The University Of Colorado, A Body Corporate | Venous access catheters and methods for portal venous system catheterization |
KR102557862B1 (en) | 2015-01-09 | 2023-07-20 | 애커러트 메디컬 테라퓨틱스 엘티디. | embolization microcatheter |
US20160287839A1 (en) * | 2015-03-31 | 2016-10-06 | Surefire Medical, Inc. | Apparatus and Method for Infusing an Immunotherapy Agent to a Solid Tumor for Treatment |
US10517603B2 (en) | 2015-06-30 | 2019-12-31 | Cosette, Lee & Harrison, LLC | Endovascular catheter with multiple capabilities |
US20180116522A1 (en) | 2015-07-10 | 2018-05-03 | Rox Medical, Inc. | Methods, systems and devices for creating a blood flow pathway to treat a patient |
US10279152B2 (en) | 2015-08-17 | 2019-05-07 | Tufts Medical Center, Inc. | Systems and methods for treating acute and chronic heart failure |
US9550046B1 (en) | 2016-02-16 | 2017-01-24 | Embolx, Inc. | Balloon catheter and methods of fabrication and use |
US10588636B2 (en) | 2017-03-20 | 2020-03-17 | Surefire Medical, Inc. | Dynamic reconfigurable microvalve protection device |
US11052224B2 (en) | 2017-05-18 | 2021-07-06 | Renovorx, Inc. | Methods for treating cancerous tumors |
US10695543B2 (en) | 2017-05-18 | 2020-06-30 | Renovorx, Inc. | Methods for treating cancerous tumors |
US11666307B2 (en) | 2017-08-10 | 2023-06-06 | Philips Image Guided Therapy Corporation | Devices, systems, and methods for real-time monitoring of fluid flow in an anuerysm |
-
2016
- 2016-03-08 US US15/064,158 patent/US20160287839A1/en not_active Abandoned
- 2016-03-23 WO PCT/US2016/023723 patent/WO2016160446A1/en active Application Filing
-
2018
- 2018-12-13 US US16/219,738 patent/US11090460B2/en active Active
-
2021
- 2021-07-14 US US17/376,115 patent/US20210338976A1/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040220511A1 (en) * | 2003-04-29 | 2004-11-04 | Neal Scott | Polymer coated device for electrically mediated drug delivery |
US20120116351A1 (en) * | 2009-12-02 | 2012-05-10 | Chomas James E | Method of Operating a Microvalve Protection Device |
US20140378951A1 (en) * | 2013-06-20 | 2014-12-25 | Philip J. Dye | Catheter |
Non-Patent Citations (1)
Title |
---|
Marcus, Assaf et al. ("Allogenic chimeric antigen receptor-modified cells for adoptive cell therapy of cancer"). 24 March 2014. Expert Opinion on Biological Therapy, Vol. 14, Issue 7. * |
Also Published As
Publication number | Publication date |
---|---|
WO2016160446A1 (en) | 2016-10-06 |
US20190111234A1 (en) | 2019-04-18 |
US11090460B2 (en) | 2021-08-17 |
US20210338976A1 (en) | 2021-11-04 |
WO2016160446A4 (en) | 2016-12-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11090460B2 (en) | Method for infusing an immunotherapy agent to a solid tumor for treatment | |
JP4436761B2 (en) | Device with expandable potion for drug release | |
US7621895B2 (en) | Needle array devices and methods | |
US8066690B2 (en) | Method for delivering medication into an arterial wall for prevention of restenosis | |
US6368315B1 (en) | Composite drug delivery catheter | |
US7292885B2 (en) | Mechanical apparatus and method for dilating and delivering a therapeutic agent to a site of treatment | |
WO2015016162A1 (en) | Biological lumen treatment device | |
US11612433B2 (en) | Laser-assisted transdermal delivery of nanoparticulates and hydrogels | |
US20080095847A1 (en) | Stimulus-release carrier, methods of manufacture and methods of treatment | |
JPH07204277A (en) | Catheter | |
JP2012513284A (en) | Apparatus and method for containing and delivering therapeutic agents | |
WO2012166168A1 (en) | Body lumen fluid delivery device | |
US20070067045A1 (en) | Systems and methods for skin wrinkle removal | |
US20170340434A1 (en) | Device useful for localized therapeutic delivery without flow obstruction | |
US20150038902A1 (en) | Infusion therapy device | |
AU1958301A (en) | Catheter with stylet lumen | |
JP2020534923A (en) | Catheter with side port and usage | |
JP6797612B2 (en) | Introducer sheath | |
WO2010090953A2 (en) | Dual-lumen catheter for medical device delivery systems | |
Filgueira et al. | Technologies for intrapericardial delivery of therapeutics and cells | |
US8152755B1 (en) | System and method for delivering a therapeutic agent with finesse | |
CN103949006A (en) | Coronary artery dilating catheter carrying ligustrazine nanoparticles | |
US20210386979A1 (en) | Balloon catheter system for infusion of micelles at high pressure | |
US20130345634A1 (en) | Delivery devices, systems and methods for delivering therapeutic agents | |
US20180104456A1 (en) | Venous anatomy drug delivery balloon |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: SUREFIRE MEDICAL, INC., COLORADO Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:JAROCH, DAVID BENJAMIN;CHOMAS, JAMES E.;REEL/FRAME:037924/0160 Effective date: 20160226 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: TRISALUS LIFE SCIENCES, INC., COLORADO Free format text: CHANGE OF NAME;ASSIGNOR:SUREFIRE MEDICAL, INC.;REEL/FRAME:057693/0506 Effective date: 20210929 |